Xarelto, also known as rivaroxaban, is a prescription blood thinner that is typically used to reduce the risk of a stroke or embolism in individuals with atrial fibrillation (A-fib), which is a heart rhythm disorder. It has been estimated that more than 1.4 million people have taken Xarelto. Patients should be aware that Xarelto is one of the relatively newer blood thinners that has been linked to serious complications.
Xarelto was first developed by pharmaceutical giant Bayer. It was marketed in the U.S. by Janssen Pharmaceuticals, which is a division of Johnson & Johnson. With sales estimated to exceed $1 billion, Xarelto is a significant component of Bayer’s business. Anyone who watches television has seen Xarelto ads featuring various athletes and celebrities.
Xarelto can cause uncontrolled bleeding in some patients. In many of these cases, there is no way to stop the bleeding, which can lead to very serious health complications and can cause death. The Suthers Law Firm is currently reviewing cases involving individuals who took Xarelto and suffered from at least one of the following, serious complications:
- (a) pulmonary embolism (PE);
- (b) uncontrolled bleeding that required hospitalization;
- (c) stroke or cerebral vascular accident (CVA); or
- (d) death.
The United States Food and Drug Administration (FDA) approved Xarelto initially in July of 2011 for use in reducing the risk of deep vein thrombosis or pulmonary embolism following hip or knee replacement surgeries. It was subsequently approved for use in treating patients suffering from A-fib in an effort to lower their risk of stroke. Additional warnings were added to the drug’s safety label, warning consumers that discontinuing the use of Xarelto prematurely could lead to an increased risk of blood clots and stroke. More warnings were added thereafter, stating that the use of Xarelto could increase the risk of a pulmonary embolism in patients who were hemodynamically unstable. Many professionals believe that the warnings given to doctors and their patients were insufficient. To-date, thousands of individuals who experienced uncontrolled bleeding that required hospitalization after taking Xarelto have filed lawsuits against the drug’s manufacturer. The cases that were filed in various Federal Courts across the United States have been consolidated into one Federal Court in the Eastern District of Louisiana. As of this time, there are more than 14,000 Xarelto lawsuits pending. The first Xarelto trials are scheduled to begin in April of 2017.
The prescription drug attorneys at Suthers Law Firm believe that individuals who experienced uncontrolled bleeding that required hospitalization after taking the drug Xarelto should be compensated for their injuries. We also join in other firms in attempting to force the drug’s manufacturer to strengthen its warnings, so that doctors and patients can make a more informed decision about whether they should prescribe or use Xarelto. If you or a loved one experienced uncontrolled bleeding that required hospitalization, a pulmonary embolism, stroke or death after taking Xarelto, you may have a valid lawsuit. You may contact the prescription drug attorneys at Suthers Law Firm by e-mail or calling us toll-free at 1-800-320-2384.